Protara Therapeutics to Participate in Upcoming Investor Conferences
Protara Therapeutics (Nasdaq: TARA), a clinical-stage company focused on cancer and rare disease therapies, has announced its participation in two upcoming investor conferences.
The company will participate in a fireside chat at the Cantor Global Healthcare Conference on September 4, 2025, at 1:35 pm ET, and deliver a corporate presentation at the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025, at 9:00 am ET. Both events will take place in New York.
Webcasts of both presentations will be available on the company's investor relations website and archived for a limited time.
Protara Therapeutics (Nasdaq: TARA), società in fase clinica focalizzata su terapie per il cancro e le malattie rare, ha comunicato la partecipazione a due prossimi incontri con investitori.
La società prenderà parte a un fireside chat al Cantor Global Healthcare Conference il 4 settembre 2025 alle 13:35 ET e terrà una presentazione aziendale all'H.C. Wainwright 27th Annual Global Investment Conference il 9 settembre 2025 alle 9:00 ET. Entrambi gli eventi si svolgeranno a New York.
I webcast di entrambe le presentazioni saranno disponibili sul sito investor relations della società e saranno archiviati per un periodo limitato.
Protara Therapeutics (Nasdaq: TARA), una compañía en fase clínica centrada en terapias para el cáncer y enfermedades raras, ha anunciado su participación en dos próximas conferencias para inversores.
La empresa participará en un fireside chat en la Cantor Global Healthcare Conference el 4 de septiembre de 2025 a las 13:35 ET y ofrecerá una presentación corporativa en la H.C. Wainwright 27th Annual Global Investment Conference el 9 de septiembre de 2025 a las 9:00 ET. Ambos eventos se celebrarán en Nueva York.
Las retransmisiones web de ambas presentaciones estarán disponibles en la web de relaciones con inversores de la compañía y se archivarán por tiempo limitado.
Protara Therapeutics (Nasdaq: TARA), 암 및 희귀질환 치료제를 개발하는 임상 단계 기업이 다가오는 두 건의 투자자 콘퍼런스에 참가한다고 발표했습니다.
회사는 2025년 9월 4일 미국 동부시간 오후 1시35분에 열리는 Cantor Global Healthcare Conference의 파이어사이드 채팅에 참여하고, 2025년 9월 9일 미국 동부시간 오전 9시 H.C. Wainwright 27th Annual Global Investment Conference에서 기업 프레젠테이션을 진행할 예정입니다. 두 행사 모두 뉴욕에서 개최됩니다.
두 발표 모두 웹캐스트로 회사의 투자자 관계 웹사이트에서 시청할 수 있으며, 일정 기간 아카이브로 제공됩니다.
Protara Therapeutics (Nasdaq: TARA), une société en phase clinique axée sur des traitements contre le cancer et les maladies rares, a annoncé sa participation à deux conférences pour investisseurs à venir.
La société participera à un fireside chat lors de la Cantor Global Healthcare Conference le 4 septembre 2025 à 13h35 ET et présentera une présentation corporate lors de la H.C. Wainwright 27th Annual Global Investment Conference le 9 septembre 2025 à 9h00 ET. Les deux événements se tiendront à New York.
Les webcasts des deux présentations seront disponibles sur le site des relations investisseurs de la société et archivés pour une durée limitée.
Protara Therapeutics (Nasdaq: TARA), ein klinisch fortgeschrittenes Unternehmen mit Schwerpunkt auf Krebs- und Orphan-Therapien, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen angekündigt.
Das Unternehmen wird an einem Fireside-Chat auf der Cantor Global Healthcare Conference am 4. September 2025 um 13:35 Uhr ET teilnehmen und eine Unternehmenspräsentation auf der H.C. Wainwright 27th Annual Global Investment Conference am 9. September 2025 um 9:00 Uhr ET halten. Beide Veranstaltungen finden in New York statt.
Webcasts beider Präsentationen werden auf der Investor-Relations-Website des Unternehmens verfügbar sein und für einen begrenzten Zeitraum archiviert.
- None.
- None.
NEW YORK, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in the following investor conferences:
- Cantor Global Healthcare Conference. A fireside chat will take place on Thursday, September 4, 2025 at 1:35 pm ET in New York.
- H.C. Wainwright 27th Annual Global Investment Conference. A corporate presentation will take place on Tuesday, September 9, 2025 at 9:00 am ET in New York.
A live webcast of the events can be accessed by visiting the Events and Presentations section of the Company’s website: https://ir.protaratx.com. The webcasts will be archived for a limited time following the presentation.
About Protara Therapeutics, Inc.
Protara is a clinical-stage biotechnology company committed to advancing transformative therapies for people with cancer and rare diseases. Protara’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase 2 trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naïve to treatment with Bacillus Calmette-Guérin (BCG), as well as a Phase 2 trial in pediatric patients with LMs. Additionally, Protara is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes. For more information, visit www.protaratx.com.
Company Contact:
Justine O'Malley
Protara Therapeutics
Justine.OMalley@protaratx.com
646-817-2836
FAQ
When is Protara Therapeutics (TARA) presenting at the Cantor Global Healthcare Conference 2025?
What time is Protara's presentation at the H.C. Wainwright Conference 2025?
How can investors access Protara Therapeutics' (TARA) conference presentations?
What type of company is Protara Therapeutics (TARA)?
